Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

The development of two distinct classes of hepatitis C antiviral agents, direct-acting antivirals (DAAs) and host-targeting antivirals (HTAs), have distinctly impacted the hepatitis C virus (HCV) field by generating higher sustained virological response (SVR) rates within infected patients, via reductions in both adverse side effects and duration of treatment when compared to the old standard of care. Today DAAs are actively incorporated into the standard of care and continue to receive the most advanced clinical trial analysis. With a multitude of innovative and potent second-generation DAA compounds currently being tested in clinical trials, it is clear that the future of DAAs looks very bright. In comparison to the other class of compounds, HTAs have been slightly less impactful, despite the fact that primary treatment regimens for HCV began with the use of an HTA - interferon alpha (IFNα). The compound was advantageous in that it provided a broad-reaching antiviral response; however deleterious side effects and viral/patient resistance has since made the compound outdated. HTA research has since moved onward to target a number of cellular host factors that are required for HCV viral entry and replication such as scavenger receptor-BI (SR-BI), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCoA reductase), cyclophilin A (CypA), fatty acid synthase (FASN) and miRNA-122. The rationale behind pursuing these HTAs is based upon the extremely low mutational rate that occurs within eukaryotic cells, thereby creating a high genetic barrier to drug resistance for anti-HCV compounds, as well as pan-genotypic coverage to all HCV genotypes and serotypes. As the end appears near for HCV, it becomes important to ask if the development of novel HTAs should also be analyzed in combination with other DAAs, in order to address potential hard-to-treat HCV patient populations. Since the treatment regimens for HCV began with the use of a global HTA, could one end the field as well?

[1]  M. Yuen,et al.  Viral hepatitis C , 2003, The Lancet.

[2]  Simon C Watkins,et al.  Fatty acid synthase is up‐regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production , 2008, Hepatology.

[3]  N. Enomoto,et al.  Specific inhibition of hepatitis C virus replication by cyclosporin A. , 2004, Biochemical and biophysical research communications.

[4]  R. Medzhitov,et al.  Type I interferons in host defense. , 2006, Immunity.

[5]  F. Penin,et al.  Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B* , 2009, Journal of Biological Chemistry.

[6]  A. García-Sastre,et al.  miR-122 is more than a shield for the hepatitis C virus genome , 2013, Proceedings of the National Academy of Sciences.

[7]  S. Lemon,et al.  Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex , 2012, Proceedings of the National Academy of Sciences.

[8]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[9]  K. Shimotohno,et al.  Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes , 2003, Hepatology.

[10]  D. Grimm.  All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  J. Bukh,et al.  MicroRNA-122 antagonism against hepatitis C virus genotypes 1–6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR , 2011, Proceedings of the National Academy of Sciences.

[12]  Sangeeta N. Bhatia,et al.  Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system , 2010, Nature Biotechnology.

[13]  P. Gallay,et al.  Profile of alisporivir and its potential in the treatment of hepatitis C , 2013, Drug design, development and therapy.

[14]  Tsunamasa Watanabe,et al.  Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial , 2003, Journal of Gastroenterology.

[15]  Feng Yang,et al.  Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex , 2009, Journal of Virology.

[16]  C. Rice,et al.  Understanding the hepatitis C virus life cycle paves the way for highly effective therapies , 2013, Nature Medicine.

[17]  N. Sakamoto,et al.  Hepatitis C Virus Replication Is Modulated by the Interaction of Nonstructural Protein NS5B and Fatty Acid Synthase , 2013, Journal of Virology.

[18]  S. Kridel,et al.  Fatty acid synthase inhibitors: new directions for oncology , 2007, Expert opinion on investigational drugs.

[19]  Chris Sander,et al.  Cellular cofactors affecting hepatitis C virus infection and replication , 2007, Proceedings of the National Academy of Sciences.

[20]  R. D. de Knegt,et al.  Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7 , 2012, Antiviral therapy.

[21]  P. Gallay,et al.  The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication* , 2009, The Journal of Biological Chemistry.

[22]  R. Schooley,et al.  Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. , 2012, The Journal of infectious diseases.

[23]  Sanjeev Arora,et al.  1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 , 2011 .

[24]  J. Liu,et al.  Crystal structure of recombinant human T-cell cyclophilin A at 2.5 A resolution. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[26]  H. Waller,et al.  The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A. , 2010, Journal of virological methods.

[27]  N. Ryder,et al.  NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon , 2006, Antimicrobial Agents and Chemotherapy.

[28]  S. Lemon,et al.  Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication , 2012, Proceedings of the National Academy of Sciences.

[29]  M. Gale,et al.  Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins , 2007, Proceedings of the National Academy of Sciences.

[30]  Jeffrey Wilusz,et al.  The highways and byways of mRNA decay , 2007, Nature Reviews Molecular Cell Biology.

[31]  S. Kotenko,et al.  Interferon-lambda: a new addition to an old family. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[32]  M. Heim.  25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end , 2013, Nature Reviews Immunology.

[33]  F. Chisari,et al.  Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. Inoue,et al.  Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. , 2005, Transplantation proceedings.

[35]  N. Kato,et al.  Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication , 2006, Journal of Virology.

[36]  A. Folgori,et al.  Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. , 2012, Journal of hepatology.

[37]  G. Lippens,et al.  DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A , 2010, PloS one.

[38]  R. Striker,et al.  Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A , 2010, PloS one.

[39]  J. Borel.  History of the discovery of cyclosporin and of its early pharmacological development. , 2002, Wiener klinische Wochenschrift.

[40]  J. McKeating,et al.  Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. , 2011, Journal of hepatology.

[41]  R. Bartenschlager,et al.  New targets for antiviral therapy of chronic hepatitis C , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[42]  K. Shimotohno,et al.  Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. , 2006, Biochemical and biophysical research communications.

[43]  D. Lavanchy,et al.  The global burden of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[44]  H. Lodish.  Molecular Cell Biology , 1986 .

[45]  J. Pawlotsky,et al.  4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS , 2011 .

[46]  J. Lemm,et al.  Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication , 2012, Antimicrobial Agents and Chemotherapy.

[47]  Judy Lieberman,et al.  Micromanaging hepatitis C virus. , 2013, The New England journal of medicine.

[48]  Teresa A. Foster,et al.  Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin Family , 2011, Antimicrobial Agents and Chemotherapy.

[49]  A. Tall,et al.  Increased HDL Cholesterol and ApoA-I in Humans and Mice Treated With a Novel SR-BI Inhibitor , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[50]  C. Cameron,et al.  HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. , 2010, Journal of hepatology.

[51]  R. Bartenschlager,et al.  The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A , 2013, PLoS pathogens.

[52]  Nahum Sonenberg,et al.  The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC , 2012, Nature Structural &Molecular Biology.

[53]  S. Kauppinen,et al.  Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.

[54]  G. Kukolj,et al.  Evaluation of Phosphatidylinositol-4-Kinase IIIα as a Hepatitis C Virus Drug Target , 2012, Journal of Virology.

[55]  P. Gallay,et al.  Cyclophilin involvement in the replication of hepatitis C virus and other viruses , 2012, Biological chemistry.

[56]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[57]  N. Heaton,et al.  Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication , 2009, Proceedings of the National Academy of Sciences.

[58]  C. Rice,et al.  CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells , 2009, The Journal of general virology.

[59]  J. Praestgaard,et al.  Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. , 2011, Antiviral research.

[60]  O. Pybus,et al.  The Global Spread of Hepatitis C Virus 1a and 1b: A Phylodynamic and Phylogeographic Analysis , 2009, PLoS medicine.

[61]  M. Shiffman,et al.  Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection , 2010, Hepatology.

[62]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[63]  E. De Clercq,et al.  The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro , 2006, Hepatology.

[64]  Chaoqun Chen,et al.  Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines. , 2013, Virology.

[65]  M. Pawłowska,et al.  The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment‐naïve hepatitis C patients , 2009, Hepatology.

[66]  R. Crabbé,et al.  The cyclophilin inhibitor Debio‐025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus , 2008, Hepatology.

[67]  C. Walsh,et al.  Active site mutants of human cyclophilin A separate peptidyl‐prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition , 1992, Protein science : a publication of the Protein Society.

[68]  P. Gallay,et al.  Curing a viral infection by targeting the host: The example of cyclophilin inhibitors , 2013, Antiviral Research.

[69]  A. Sluder,et al.  The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. , 2012, Journal of hepatology.

[70]  G. Fischer,et al.  SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro , 2009, Antimicrobial Agents and Chemotherapy.

[71]  E. Domingo,et al.  Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype , 2013, Journal of Virology.

[72]  P. Sarnow,et al.  Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA , 2005, Science.